InflaRx (IFRX) Cost of Revenue (2023 - 2025)
Historic Cost of Revenue for InflaRx (IFRX) over the last 3 years, with Q3 2025 value amounting to $85210.1.
- InflaRx's Cost of Revenue rose 693.86% to $85210.1 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 billion, marking a year-over-year decrease of 9672.06%. This contributed to the annual value of $3.6 million for FY2024, which is 9999.94% down from last year.
- Per InflaRx's latest filing, its Cost of Revenue stood at $85210.1 for Q3 2025, which was up 693.86% from $2.7 million recorded in Q2 2025.
- InflaRx's 5-year Cost of Revenue high stood at $298.2 billion for Q4 2023, and its period low was $79681.3 during Q3 2024.
- Moreover, its 3-year median value for Cost of Revenue was $337760.2 (2023), whereas its average is $30.8 billion.
- Its Cost of Revenue has fluctuated over the past 5 years, first crashed by 9999.9% in 2024, then surged by 407939124.8% in 2025.
- Over the past 3 years, InflaRx's Cost of Revenue (Quarter) stood at $298.2 billion in 2023, then plummeted by 100.0% to $3.0 million in 2024, then plummeted by 97.17% to $85210.1 in 2025.
- Its last three reported values are $85210.1 in Q3 2025, $2.7 million for Q2 2025, and $9.8 billion during Q1 2025.